/GHRS
GHRS Stock - GH Research PLC
Healthcare|BiotechnologyNASDAQ
$12.96+1.89%
+$0.24 (+1.89%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+108.3%upside
Target: $27.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GHRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.83 – $13.09
TARGET (TP)$27.00
STOP LOSS$11.92
RISK/REWARD1:13.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$20.50
52W Low$6.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-50,312,000 | $-41,222,000 | $-30,554,000 | $-15,100,000 | $-446,000 |
| Net Income | $-38,961,000 | $-35,587,000 | $-22,456,000 | $-9,202,000 | $-446,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.75 | $-0.68 | $-0.14 | $-0.18 | $-0.01 |
Company Overview
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$33
Average Target
↑ 155.7% Upside
Now
$14
Low
$33
Average
$66
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Needham | Initiation | Buy | $19 |
| June 4th 2025 | Cantor Fitzgerald | Resumed | Overweight | $25 |
| March 13th 2025 | Guggenheim | Initiation | Buy | $32 |
| March 7th 2025 | RBC Capital Mkts | Initiation | Outperform | $31 |
| February 13th 2025 | Cantor Fitzgerald | Initiation | Overweight | $14 |
| August 16th 2022 | H.C. Wainwright | Initiation | Buy | $45 |
| June 16th 2022 | ROTH Capital | Initiation | Buy | $66 |
Earnings History & Surprises
GHRSBeat Rate
83%
Last 18 quarters
Avg Surprise
+26.5%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$-0.23
Q4 2025
EPS Surprise History
Q1 24
-5.0%
$-0.21vs$-0.20
Q2 24
+31.8%
$-0.15vs$-0.22
Q3 24
+16.7%
$-0.20vs$-0.24
Q4 24
+8.0%
$-0.23vs$-0.25
Q1 25
+26.1%
$-0.17vs$-0.23
Q2 25
+68.9%
$-0.19vs$-0.61
Q3 25
+31.8%
$-0.15vs$-0.22
Q4 25
0.0%
$-0.23vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.23 | $-0.23 | 0.0% | = MET |
Q3 2025 | Aug 7, 2025 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.61 | $-0.19 | +68.9% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q3 2024 | Sep 3, 2024 | $-0.24 | $-0.20 | +16.7% | ✓ BEAT |
Q2 2024 | May 3, 2024 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.20 | $-0.11 | +45.0% | ✓ BEAT |
Q3 2023 | Aug 23, 2023 | $-0.32 | $-0.15 | +53.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.18 | $-0.32 | -77.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.17 | $-0.01 | +94.1% | ✓ BEAT |
Q3 2022 | Aug 23, 2022 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q2 2022 | May 18, 2022 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q1 2022 | Mar 28, 2022 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q4 2021 | Dec 6, 2021 | $-0.09 | $-0.04 | +55.6% | ✓ BEAT |
Q3 2021 | Sep 23, 2021 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q2 2021 | Jun 28, 2021 | — | $-0.01 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $35
➖ NeutralBenzinga•Nov 10, 2025, 05:11 PM
GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:19 PM
Needham Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $19
📈 PositiveBenzinga•Oct 13, 2025, 10:11 AM
GH Research to Present Long-Term Data on Depression Treatment at 38th European Neuropsychopharmacology Congress
📈 PositiveBenzinga•Oct 9, 2025, 11:14 AM
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
📈 PositiveBenzinga•Aug 25, 2025, 06:53 PM•Also: , ,
Frequently Asked Questions about GHRS
What is GHRS's current stock price?
GH Research PLC (GHRS) is currently trading at $12.96 per share. The stock has moved +1.89% today.
What is the analyst price target for GHRS?
The average analyst price target for GHRS is $27.00, based on 1 analyst.
What sector is GH Research PLC in?
GH Research PLC operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GHRS's market cap?
GH Research PLC has a market capitalization of $0.80 billion, making it a small-cap company.
Does GHRS pay dividends?
No, GH Research PLC does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
PVLA
Palvella Therapeutics, Inc.
$99.73
Mkt Cap: $1.2B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SPRY
ARS Pharmaceuticals, Inc.
$10.49
Mkt Cap: $1.0B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to GHRS for comparison